Citius Pharmaceuticals, Inc. (CTXR) Income Statement
CTXR FY2025 at a glance
Fiscal year ended September 30, 2025 · U.S. dollarsCTXR revenue and net income
CTXR growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CTXR quarterly EPS vs estimates
Citius Pharmaceuticals beat the analyst EPS estimate in 2 of the last 8 quarters.
CTXR income statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $214,250 | $209,611 | $194,316 | $179,677 | $164,868 | $152,364 | $893 | $1,753 | $2,632 | $1,343 |
| Gross profit | −$214,250 | −$209,611 | −$194,316 | −$179,677 | −$164,868 | −$152,364 | −$893 | −$1,753 | −$2,632 | −$1,343 |
| Research & development | $9.2M | $11.9M | $14.8M | $17.7M | $12.2M | $8.8M | $8.6M | $6.6M | $2.9M | $2.9M |
| Sales, general & admin | $18.5M | $18.2M | $21.9M | $15.7M | $11.3M | $8.9M | $7.0M | $7.2M | $7.1M | $4.5M |
| Total operating expenses | $38.3M | $42.0M | $36.7M | $33.3M | $23.4M | $17.6M | $15.6M | $13.8M | $10.0M | $7.4M |
| Operating income | −$38.5M | −$42.0M | −$36.7M | −$33.3M | −$23.5M | −$17.7M | −$15.6M | −$13.8M | −$10.0M | −$7.4M |
| Interest income | $110,081 | $758,000 | $1.2M | $251,399 | $261,825 | $68,066 | $52,660 | $0 | $398,640 | $806 |
| Interest expense | $267,782 | — | — | $251,399 | $10,839 | $15,673 | $16,443 | $15,838 | $850,789 | $8,994 |
| Income before taxes | −$38.7M | −$38.8M | −$32.0M | −$33.1M | −$23.1M | −$17.5M | −$15.6M | −$12.5M | −$10.4M | −$8.3M |
| Income taxes | $1.1M | $576,000 | $576,000 | $576,000 | $70,756 | $125,880 | $16,443 | $1.3M | $850,789 | $8,994 |
| Net income | −$37.4M | −$39.1M | −$32.5M | −$33.6M | −$23.1M | −$17.5M | −$15.6M | −$12.5M | −$10.4M | −$8.3M |
| EBITDA | −$38.2M | −$38.6M | −$36.5M | −$33.1M | −$23.4M | −$17.6M | −$15.5M | −$13.8M | −$10.0M | −$7.4M |
| EPS (diluted) | −$3.48 | −$8.61 | −$5.02 | −$5.50 | −$2.42 | −$11.50 | −$15.66 | −$5.73 | −$12.56 | −$53.99 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $1.7M | $3.9M | $0 | $0 | $0 | $155,926 | $155,926 | $0 | $0 | $0 | $0 |
| Cost of revenue | $2.2M | $2.0M | $1.4M | $62,038 | $41,367 | $56,010 | $54,835 | $53,685 | $52,848 | $52,070 | $51,008 | $49,969 |
| Gross profit | −$718,367 | −$381,892 | $2.6M | −$62,038 | −$41,367 | −$56,010 | −$54,835 | −$53,685 | −$52,848 | −$52,070 | −$51,008 | −$49,969 |
| Research & development | $1.1M | $1.6M | $1.6M | $1.6M | $1.6M | $3.8M | $2.1M | $2.9M | $2.8M | $3.6M | $2.6M | $2.9M |
| Sales, general & admin | $6.1M | $26.4M | $5.7M | $1.2M | $7.2M | $7.5M | $7.9M | $8.1M | $7.9M | $7.4M | $6.7M | $7.2M |
| Total operating expenses | $11.0M | $31.8M | $11.6M | $8.4M | $8.7M | $11.3M | $10.0M | $11.0M | $10.6M | $10.9M | $9.3M | $10.1M |
| Operating income | −$11.7M | −$32.2M | −$9.0M | −$8.4M | −$8.8M | −$11.3M | −$10.0M | −$11.1M | −$10.6M | −$11.0M | −$9.3M | −$10.1M |
| Interest income | $116,691 | $53,584 | $45,097 | $53,423 | $20,637 | $13,413 | $22,608 | $117,314 | $204,843 | $182,205 | $253,638 | $324,813 |
| Interest expense | $411,224 | $33,031 | $155,538 | $95,520 | $172,262 | $0 | $0 | — | $0 | — | — | $4.1M |
| Income before taxes | −$12.0M | −$28.3M | −$9.1M | −$8.5M | −$8.9M | −$11.2M | −$10.0M | −$10.9M | −$10.4M | −$8.4M | −$9.1M | −$9.8M |
| Income taxes | −$107,347 | −$231,210 | $264,240 | $264,240 | $264,240 | $264,240 | $264,240 | $144,000 | $144,000 | $144,000 | $144,000 | $144,000 |
| Net income | −$8.9M | −$21.2M | −$8.2M | −$8.0M | −$8.8M | −$10.9M | −$9.8M | −$10.8M | −$10.6M | −$8.5M | −$9.2M | −$9.9M |
| EBITDA | −$10.0M | −$30.4M | −$8.5M | −$8.3M | −$8.7M | −$11.2M | −$10.0M | −$11.0M | −$10.6M | −$11.0M | −$9.3M | −$10.1M |
| EPS (diluted) | −$0.34 | −$0.95 | −$0.38 | −$0.11 | −$0.80 | −$1.27 | −$1.30 | −$5.80 | −$1.50 | −$1.25 | −$0.06 | −$1.75 |
| Gross margin | −48.1% | −22.9% | 65.5% | — | — | — | −35.2% | −34.4% | — | — | — | — |
| Operating margin | −785.4% | −1,931.0% | −228.7% | — | — | — | −6,438.7% | −7,087.0% | — | — | — | — |
| Net margin | −593.3% | −1,273.4% | −208.4% | — | — | — | −6,264.7% | −6,920.1% | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CTXR's financial statements (latest annual report filed December 23, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CTXR financial results
Citius Pharmaceuticals reported no revenue in fiscal year 2025 (ended September 30, 2025). It had a net loss of $37.4 million. Diluted earnings per share came to −$3.48.
See the CTXR stock overview for the latest quote and news, or the CTXR chart for price history and technical indicators.
CTXR income statement FAQ
Does Citius Pharmaceuticals have revenue?
Citius Pharmaceuticals reported no revenue for fiscal year 2025, which ended on September 30, 2025.
Is Citius Pharmaceuticals profitable?
No. Citius Pharmaceuticals reported a net loss of $37.4 million in fiscal 2025.
How much does Citius Pharmaceuticals spend on research and development?
Citius Pharmaceuticals spent $9.2 million on research and development in fiscal 2025.
What are Citius Pharmaceuticals's earnings per share?
Citius Pharmaceuticals earned $-3.48 per diluted share in fiscal 2025, compared with $-8.61 a year earlier.
When does Citius Pharmaceuticals's fiscal year end?
Citius Pharmaceuticals's fiscal year ends in September. The latest annual report covers the year ended September 30, 2025 and was filed on December 23, 2025.